ARBUTUS BIOPHARMA CORP (ABUS)
CA03879J1003 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 26.29M | 30.80M | 109.30M | 52.30M | 31.80M | |||
| Marketable Securities | 99.72M | 116.10M | 46.00M | 71.00M | 59.00M | |||
| Receivables | 1.78M | 1.40M | 900.00K | 1.30M | 1.20M | |||
| Other Current Assets | 4.25M | 2.90M | 4.40M | 3.10M | 1.80M | |||
| Total Current Assets | 132.03M | 151.10M | 160.70M | 127.70M | 93.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 6.09M | 6.80M | 8.10M | 9.30M | 11.40M | |||
| Investments And Advances | 6.28M | 37.40M | 35.70M | N/A | 0.00 | |||
| Goodwill | N/A | N/A | N/A | N/A | 0.00 | |||
| Intangibles | N/A | N/A | N/A | N/A | 0.00 | |||
| Other Non-Current Assets | 0.00 | 100.00K | 100.00K | 0.00 | 300.00K | |||
| Total Non-Current Assets | 12.37M | 44.30M | 43.80M | 9.40M | 11.70M | |||
| TOTAL ASSETS | 144.40M | 195.40M | 204.50M | 137.10M | 105.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 7.47M | 12.90M | 8.00M | 6.30M | 5.20M | |||
| Accounts Payable | 3.22M | 3.50M | 3.20M | 3.00M | 2.40M | |||
| Other Current Liabilities | 11.79M | 16.50M | 0.00 | 300.00K | 300.00K | |||
| Total Current Liabilities | 22.49M | 32.90M | 11.20M | 9.50M | 7.80M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | N/A | N/A | N/A | N/A | 0.00 | |||
| Other Non-Current Liabilities | 15.90M | 25.70M | 23.80M | 25.60M | 25.00M | |||
| Total Non-Current Liabilities | 15.90M | 25.70M | 23.80M | 25.60M | 25.00M | |||
| TOTAL LIABILITIES | 38.38M | 58.60M | 35.00M | 35.10M | 32.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.28B | -1.20B | -1.13B | -1.05B | -970.10M | |||
| Additional Paid In Capital | 81.27M | 72.40M | 65.50M | 60.80M | 55.20M | |||
| Common Shares | 1.35B | 1.32B | 1.29B | 1.14B | 1.04B | |||
| Other Shareholders' Equity | -48.42M | -50.50M | -48.30M | -48.20M | -48.20M | |||
| Shares Outstanding | 169.87M | 157.50M | 145.00M | 89.70M | 64.80M | |||
| Tangible Book Value per Share | 0.62 | 0.87 | 1.17 | -0.53 | -1.00 | |||
| Total Shareholders' Equity | 106.02M | 136.90M | 169.40M | 102.00M | 72.70M | |||
| TOTAL LIABILITIES AND EQUITY | 144.40M | 195.40M | 204.50M | 137.10M | 105.50M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 5.87 | 4.59 | 14.35 | 13.44 | 12.03 | |||
| Return On Assets (ROA) | -50.45% | -35.55% | -43.22% | -55.34% | -156.27% | |||
| Return On Equity (ROE) | -68.71% | -50.74% | -52.18% | -74.38% | -226.78% | |||
All data in USD